356 related articles for article (PubMed ID: 31810554)
1. Type I interferons and dendritic cells in cancer immunotherapy.
Sprooten J; Agostinis P; Garg AD
Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554
[TBL] [Abstract][Full Text] [Related]
2. Type I interferons in anticancer immunity.
Zitvogel L; Galluzzi L; Kepp O; Smyth MJ; Kroemer G
Nat Rev Immunol; 2015 Jul; 15(7):405-14. PubMed ID: 26027717
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R; Zhu B; Chen D
Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
5. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
7. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.
Rizza P; Moretti F; Capone I; Belardelli F
Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627
[TBL] [Abstract][Full Text] [Related]
8. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1
Tsuchiya N; Zhang R; Iwama T; Ueda N; Liu T; Tatsumi M; Sasaki Y; Shimoda R; Osako Y; Sawada Y; Kubo Y; Miyashita A; Fukushima S; Cheng Z; Nakaki R; Takubo K; Okada S; Kaneko S; Ihn H; Kaisho T; Nishimura Y; Senju S; Endo I; Nakatsura T; Uemura Y
Cell Rep; 2019 Oct; 29(1):162-175.e9. PubMed ID: 31577946
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
10. Type I and II interferons toward ideal vaccine and immunotherapy.
Temizoz B; Ishii KJ
Expert Rev Vaccines; 2021 May; 20(5):527-544. PubMed ID: 33993812
[No Abstract] [Full Text] [Related]
11. Between biology and medicine: perspectives on the use of dendritic cells in anticancer therapy.
Szczygieł A; Pajtasz-Piasecka E
Postepy Hig Med Dosw (Online); 2017 Nov; 71(0):921-941. PubMed ID: 29176007
[TBL] [Abstract][Full Text] [Related]
12. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation.
Fekete T; Sütö MI; Bencze D; Mázló A; Szabo A; Biro T; Bacsi A; Pazmandi K
Front Immunol; 2018; 9():3070. PubMed ID: 30622542
[TBL] [Abstract][Full Text] [Related]
13. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Rivera Vargas T; Benoit-Lizon I; Apetoh L
Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
[TBL] [Abstract][Full Text] [Related]
14. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
15. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
Seya T; Azuma M; Matsumoto M
Expert Opin Ther Targets; 2013 May; 17(5):533-44. PubMed ID: 23414438
[TBL] [Abstract][Full Text] [Related]
16. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.
Rizza P; Moretti F; Belardelli F
Autoimmunity; 2010 Apr; 43(3):204-9. PubMed ID: 20187707
[TBL] [Abstract][Full Text] [Related]
17. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.
Diamond JM; Vanpouille-Box C; Spada S; Rudqvist NP; Chapman JR; Ueberheide BM; Pilones KA; Sarfraz Y; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Aug; 6(8):910-920. PubMed ID: 29907693
[TBL] [Abstract][Full Text] [Related]
18. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.
Brown M
Cancer Treat Res; 2022; 183():91-129. PubMed ID: 35551657
[TBL] [Abstract][Full Text] [Related]
19. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
Garg AD; Agostinis P
Immunol Rev; 2017 Nov; 280(1):126-148. PubMed ID: 29027218
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.
Vitiello GAF; Ferreira WAS; Cordeiro de Lima VC; Medina TDS
Front Immunol; 2021; 12():782852. PubMed ID: 34925363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
